Expert Roundtable: Comorbidities in Atopic Dermatitis
Atopic dermatitis, especially severe atopic dermatitis, is associated with allergic, autoimmune, and cardiovascular comorbidities.
Atopic Dermatitis
Dupilumab Induces Rapid Improvement of Atopic Dermatitis in Japanese Adults
Data from this analysis indicate that dupilumab induces rapid improvements in AD that can be maintained long term in a significant percentage of Japanese adults with moderate to severe AD, with prolonged benefits in terms of both pruritus and QoL.
Moderate to Severe Atopic Dermatitis Associated With Increased Risk for Atrial Fibrillation
The study data showed a 20% increased long-term risk for atrial fibrillation in patients with hospital-diagnosed moderate to severe atopic dermatitis.
Abrocitinib Effective in Second Phase 3 Atopic Dermatitis Trial
Pfizer announced positive topline results from the phase 3 JADE MONO-2 trial of abrocitinib, an oral Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis.
Jynneos Gets FDA Approval for Smallpox, Monkeypox Prevention
The FDA has approved Jynneos (smallpox and monkeypox vaccine, live, non-replicating; Bavarian Nordic) for the prevention of smallpox and monkeypox in adults 18 years of age and older determined to be at high risk for these infections.
Patients, Providers Agree on Outcome Measures for Inflammatory Skin Disorders
Patients and providers agreed that Skindex instruments are important complements to patient global assessments for determining disease burden and severity in clinical practice.
Dupilumab Associated With Favorable Benefit/Risk Ratio for Treatment of Atopic Dermatitis, Phase 3 Safety Data Indicates
This study supports the use of dupilumab as a systemic treatment for long-term management of moderate to severe AD without routine laboratory monitoring in clinical practice.
Higher Self-Reported Severity of AD Indicative of Lower Health-Related Quality of Life
From the patient’s perspective, higher atopic dermatitis severity is associated with poorer HRQoL — a burden that may provide motivation for more effective management of atopic dermatitis.
Dupilumab Shows Significant Clinical Improvement for Atopic Dermatitis Across Racial Subgroups
Notable improvement with dupilumab in the treatment of moderate to severe atopic dermatitis was seen in all racial subgroups.
Gluten Does Not Increase Risk for Psoriatic Disease/Atopic Dermatitis in Women
Findings do not support dietary restriction of gluten intake as a means of preventing inflammatory skin and musculoskeletal conditions in women.
Next post in Psoriasis
